CRO/Sponsor

In this interview, Linda Rawlings, VP of Neurodegenerative Development at Synteract, elaborates on addressing the challenges of neurodegenerative disease clinical trials.

Joe Pollarine, Head of GxP Systems Strategy Director at Janssen, recently spoke about CRO oversight models and will expand on these models in this interview.

As the size, complexity, duration, cost, and globalization of clinical trials has grown, pharmaceutical and biotech companies have moved to outsource clinical activities to CROs to achieve a wide range of objectives.

There are key cultural differences to be aware of before conducting clinical trials in Japan.

Proposed partnership model explores the value of establishing alliances between CROs and networks of small and emerging biopharma companies.

Exploring sourcing model options for appropriate incorporation of DMCs into a clinical program.

A two-phase statistical analysis identifies the key performance drivers in clinical trial startup.

MAPs can effectively address unmet patient needs and become a cornerstone of product strategy.

Pharma needs to find a balance in working with Sponsors and CROs in order to streamline the study processes.

Clinical research organizations should look to peer-to-peer mentoring for professional development.

Companies trusting each other and looking out for each other's interests is the hallmark of outsourcing.

The goal is to have an evidence development framework that can answer a range of questions simultaneously.

Oncology clinical trials: A case for Russia and Eastern Europe.

Accelerating the discovery and delivery of personalized medicine.

Increasing development costs and high failure rates require earlier integration of imaging data in the Phase I setting.

Life can change in an instant, but there is one thing that always abides: hope.

Options have emerged that make DIY EDC technology more accessible to smaller organizations.

The region has an appropriate population size, solid infrastructure, experienced nvestigators, and short timelines.

A survey of clinical research professionals asked: What makes you a successful project leader?

Conversion from paper to ePRO for an instrument designed to assess diabetes' impact on quality of life.

Modeling and simulation has been heralded for some time as a possible answer to the industry's woes.

Demonstrating biosimilarity is highly dependent on the unique characteristics of the product.

From tactical to strategic: tracking the evolution of global clinical supply chain management.

A well designed CTCP can keep everyone motivated and focused on achieving trial objectives.

The major industry milestones of the past 20 years.

The adoption of new, consistent definitions are needed to help demystify late phase trials.

Continual change is coming as sponsors' sourcing requirements diverge from the major CROs.

Where do CRO's turn next? What does pharma do about it?

Cancer trial recruitment is struggling-adult participation is limited.

Optimizing early phase trials key to the success of novel cytotoxics and targeted therapies.